Literature DB >> 193798

Efficacy of herpes simplex virus type 1 immunization in protecting against acute and latent infection by herpes simplex virus type 2 in mice.

R R McKendall.   

Abstract

ICR mice were immunized with herpes simplex virus type 1 (HSV-1) and later challenged with HSV-2 by footpad inoculation. Both immunized animals and age-matched, nonimmunized controls were observed for ascending neurological disease and latent infection of spinal ganglia resulting from the HSV-2 challenge. Control animals had a 78% incidence of acute and latent infection compared with a 1.7% incidence in immunized mice. The data show immunity to HSV-1 is protective against both acute and latent infection by HSV-2.

Entities:  

Mesh:

Year:  1977        PMID: 193798      PMCID: PMC421016          DOI: 10.1128/iai.16.2.717-719.1977

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  17 in total

1.  Latent infection of sensory ganglia with herpes simplex virus: efficacy of immunization.

Authors:  R W Price; M A Walz; C Wohlenberg; A L Notkins
Journal:  Science       Date:  1975-05-30       Impact factor: 47.728

2.  Invasion of the central nervous system by herpes simplex virus type 1 after subcutaneous inoculation of immunosuppressed mice.

Authors:  J E Oakes
Journal:  J Infect Dis       Date:  1975-01       Impact factor: 5.226

3.  Role for cell-mediated immunity in the resistance of mice to subcutaneous herpes simplex virus infection.

Authors:  J E Oakes
Journal:  Infect Immun       Date:  1975-07       Impact factor: 3.441

Review 4.  A review of the identification and titration of antibodies to herpes simplex viruses type 1 and type 2 in human sera.

Authors:  G Plummer
Journal:  Cancer Res       Date:  1973-06       Impact factor: 12.701

5.  Pathogenesis of herpetic neuritis and ganglionitis in mice: evidence for intra-axonal transport of infection.

Authors:  M L Cook; J G Stevens
Journal:  Infect Immun       Date:  1973-02       Impact factor: 3.441

6.  Effect of antithymocyte serum on herpesvirus hominis (type 1) infection in adult mice.

Authors:  A J Nahmias; M S Hirsch; J H Kramer; F A Murphy
Journal:  Proc Soc Exp Biol Med       Date:  1969-11

7.  The incidence of Herpesvirus hominis antibody in the population.

Authors:  I W Smith; J F Peutherer; F O MacCallum
Journal:  J Hyg (Lond)       Date:  1967-09

8.  Comparative studies of type 1 and type 2 & 'herpes simplex' viruses.

Authors:  G Plummer; J L Waner; C P Bowling
Journal:  Br J Exp Pathol       Date:  1968-04

9.  Mechanism of immunologic resistance to herpes simplex virus 1 (HSV-1) infection.

Authors:  B Rager-Zisman; A C Allison
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

10.  Type 1 and type 2 herpes simplex viruses: serological and biological differences.

Authors:  G Plummer; J L Waner; A Phuangsab; C R Goodheart
Journal:  J Virol       Date:  1970-01       Impact factor: 5.103

View more
  15 in total

1.  Latent herpes simplex virus in ganglia of mice after primary infection and reinoculation at a distant site.

Authors:  R J Klein; A E Friedman-Kien; E Brady
Journal:  Arch Virol       Date:  1978       Impact factor: 2.574

2.  Protective effect of an oral infection with herpes simplex virus type 1 against subsequent genital infection with herpes simplex virus type 2.

Authors:  B Sturn; K E Schneweis
Journal:  Med Microbiol Immunol       Date:  1978-07-04       Impact factor: 3.402

3.  Follow-up report on 50 subjects vaccinated against herpes genitalis with Skinner vaccine.

Authors:  G R Skinner; C G Fink; M Cowan; A Buchan; A Fuller; C E Hartley; J Durham; C Wiblin; J Melling
Journal:  Med Microbiol Immunol       Date:  1987       Impact factor: 3.402

4.  Initial herpes simplex virus type 1 infection prevents ganglionic superinfection by other strains.

Authors:  Y M Centifanto-Fitzgerald; E D Varnell; H E Kaufman
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

5.  Immune responses in mice against herpes simplex virus: mechanisms of protection against facial and ganglionic infections.

Authors:  H J Zweerink; D Martinez; R J Lynch; L W Stanton
Journal:  Infect Immun       Date:  1981-01       Impact factor: 3.441

6.  The influence of different modes of immunization on the experimental genital herpes simplex virus infection of mice.

Authors:  K E Schneweis; J Gruber; J Hilfenhaus; A Möslein; M Kayser; M H Wolff
Journal:  Med Microbiol Immunol       Date:  1981       Impact factor: 3.402

7.  Preparation and immunogenicity of vaccine Ac NFU1 (S-) MRC towards the prevention of herpes genitalis.

Authors:  G R Skinner; C B Woodman; C E Hartley; A Buchan; A Fuller; J Durham; M Synnott; J C Clay; J Melling; C Wiblin; J Wilkins
Journal:  Br J Vener Dis       Date:  1982-12

8.  Immunogenicity and protective efficacy in a rhesus monkey model of vaccine Ac NFUi(S-) MRC against primary type 2 herpes simplex virus infection.

Authors:  G R Skinner; A Buchan; D Williams; J Marsden; C Hartley; G Wilbanks; M Turyk; E S Namkoong
Journal:  Br J Exp Pathol       Date:  1982-08

9.  Immunogenicity of herpes simplex virus glycoproteins gC and gB and their role in protective immunity.

Authors:  J Glorioso; C H Schröder; G Kumel; M Szczesiul; M Levine
Journal:  J Virol       Date:  1984-06       Impact factor: 5.103

10.  The preparation, efficacy and safety of 'antigenoid' vaccine NFU1 (S-L+) MRC toward prevention of herpes simplex virus infections in human subjects.

Authors:  G R Skinner; A Buchan; C E Hartley; S P Turner; D R Williams
Journal:  Med Microbiol Immunol       Date:  1980       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.